Who is funding the study?
The iPrEx study is being funded by the Division of AIDS at the National Institute of Allergy and Infectious Diseases (NIAID), which is part of the U.S. National Institutes of Health (NIH), through a grant to the J. David Gladstone Institutes, a non-profit independent research organization affiliated with the University of California at San Francisco. Additional funding is provided by the Bill & Melinda Gates Foundation. The company that manufactures tenofovir/emtricitabine, Gilead Sciences, is donating the study drug but is not providing funding for the trial.
Related Questions
- Am I eligible for LASDD funding if I am a student in a discipline outside the social sciences but study issues of organized crime or drug trafficking?
- Is the continuation of a study (i.e. new grant funding) using the same protocol number considered a "new" study under HIPAA guidelines?
- How far in advance of the study should I submit the IIS funding application?
